Shot Block Flu - Search News

FDA Refuses To Review Moderna’s Flu Vaccine

Moderna says FDA refuses to review its application for flu vaccine

Moderna noted the FDA did not identify any specific safety concerns with the vaccine and that the rejection was inconsistent with previous feedback.

· 22h

Kennedy-era FDA changes vaccine review process, blocks Moderna application

pharmaphorum · 14h

Moderna cries foul as FDA blocks filing of mRNA flu shot

· 1d

FDA declines to review Moderna's mRNA flu shot

The Food and Drug Administration rejected Moderna’s application for its mRNA-based flu vaccine, the drugmaker said Tuesday.

· 15h

F.D.A. Refuses to Review Moderna Flu Vaccine

· 1d

FDA refuses to review Moderna’s application for mRNA flu vaccine, company says

· 2h

FDA officials defend decision to not review Moderna’s new flu vaccine

In a press conference, a senior FDA official said the decision was the result of Moderna exposing certain trial participants to sub-standard care against the advice of the federal regulators.

· 1d

FDA refuses to review Moderna's influenza vaccine application

· 1d

Moderna says FDA refuses its application for new mRNA flu vaccine

Devdiscourse

FDA Blocks Moderna's mRNA Flu Vaccine Application Amid Heightened Scrutiny

The FDA has refused to consider Moderna's application for a new flu vaccine using mRNA technology, criticizing the design of its clinical trial. Despite the agency's concerns, Moderna argues there are no safety or efficacy issues.

AOL

Wondering if you should get a flu shot? Here’s what science says

Flu is making people miserable from coast to coast, thanks in large part to a new strain called subclade K. That’s why infectious disease experts are telling people to run, not walk, to get this season’s flu shot if they haven’t yet. But you may be ...

1don MSN

Seasonal flu antibodies can also target avian flu to build immunity against potential pandemic risks

Are seasonal flu antibodies also effective against avian flu? A team from the University of Geneva (UNIGE) has shown that a specific type of antibody associated with the former virus—already present throughout the population—may offer baseline protection against the latter.